Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03961698
Title Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (MARIO-3)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.

renal cell carcinoma

triple-receptor negative breast cancer


Atezolizumab + Bevacizumab + IPI-549

Atezolizumab + IPI-549 + Nab-paclitaxel

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.